Considering the cost-effectiveness of statins in family practice in Turkey from a payer perspectiveReportar como inadecuado




Considering the cost-effectiveness of statins in family practice in Turkey from a payer perspective - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

The percentage of mortality caused by cardio-vascular events in European Countries and European Union Countries is respectively 49% and 42% of all mortality causes. Our estimates about cardiovascular mortality in Turkey depend on TEKHARF Hearth Disease and Risk Factors in Turkish Adults which depended on a 12 year observation. It has been reported that cardio-vascular mortality rates for Turkey in men and women were 0.082% and 0.043% respectively. In Turkey, Atorvastatin, Fluvastatin, Pravastatin, Rosuvastatin and Simvastatin are the different alternatives found in the statin market. All stat-ins are reimbursed by insurance companies. The aim of this study is to determine the cost- effectiveness of statins. In conclusion, simvas-tatin and rosuvastatin comprised the optimal two statin alternatives.

KEYWORDS

Hypercholesterolemia; Cardiovascular Disease; Cost-Effectiveness Analysis; Decision Analysis Mode

Cite this paper

Koçkaya, G. , Wertheimer, A. , Koçkaya, P. and Esen, A. 2009 Considering the cost-effectiveness of statins in family practice in Turkey from a payer perspective. Health, 1, 274-280. doi: 10.4236-health.2009.14044.





Autor: Güvenç Koçkaya1, Albert Wertheimer2, Pınar Daylan Koçkaya3, Ahmet Esen1

Fuente: http://www.scirp.org/



DESCARGAR PDF




Documentos relacionados